F. Sheridan John's Insider Trades & SAST Disclosures
F. Sheridan John's most recent trade in Tandem Diabetes Care Inc was a trade of 23,929 Restricted Stock Unit done . Disclosure was reported to the exchange on May 15, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern F. Sheridan John.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 23,929 | 47,858 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 23,929 | 108,479 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.70 per share. | 15 May 2025 | 12,152 | 96,327 (0%) | 0% | 22.7 | 275,850 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 5,472 | 21,886 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.70 per share. | 15 May 2025 | 5,472 | 87,329 (0%) | 0% | 22.7 | 124,214 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.70 per share. | 15 May 2025 | 2,779 | 84,550 (0%) | 0% | 22.7 | 63,083 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 2,236 | 0 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 2,236 | 82,993 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 15.64 per share. | 15 May 2025 | 1,359 | 80,368 (0%) | 0% | 15.6 | 21,255 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.70 per share. | 15 May 2025 | 1,136 | 81,857 (0%) | 0% | 22.7 | 25,787 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 792 | 0 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 792 | 81,160 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.70 per share. | 15 May 2025 | 403 | 80,757 (0%) | 0% | 22.7 | 9,148 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2025 | 26,047 | 0 | - | - | Performance Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2025 | 26,047 | 89,017 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.34 per share. | 25 Feb 2025 | 10,008 | 79,009 (0%) | 0% | 33.3 | 333,667 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2025 | 6,732 | 66,389 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2025 | 6,732 | 0 | - | - | Performance Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.34 per share. | 25 Feb 2025 | 3,419 | 62,970 (0%) | 0% | 33.3 | 113,989 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 5,472 | 27,358 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 5,472 | 61,754 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 2,237 | 2,236 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 2,237 | 57,083 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.47 per share. | 18 Feb 2025 | 2,097 | 59,657 (0%) | 0% | 33.5 | 70,187 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.47 per share. | 18 Feb 2025 | 801 | 56,282 (0%) | 0% | 33.5 | 26,809 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 793 | 55,130 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 793 | 792 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.47 per share. | 18 Feb 2025 | 284 | 54,846 (0%) | 0% | 33.5 | 9,505 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2024 | 5,471 | 56,729 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2024 | 5,471 | 32,830 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.34 per share. | 15 Nov 2024 | 2,773 | 53,956 (0%) | 0% | 27.3 | 75,814 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2024 | 2,236 | 4,473 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2024 | 2,236 | 52,392 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.34 per share. | 15 Nov 2024 | 1,134 | 51,258 (0%) | 0% | 27.3 | 31,004 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2024 | 792 | 1,585 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2024 | 792 | 50,558 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.34 per share. | 15 Nov 2024 | 402 | 50,156 (0%) | 0% | 27.3 | 10,991 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 15.64 per share. | 15 Nov 2024 | 381 | 54,337 (0%) | 0% | 15.6 | 5,959 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2024 | 5,472 | 38,301 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2024 | 5,472 | 52,540 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.82 per share. | 15 Aug 2024 | 2,774 | 49,766 (0%) | 0% | 43.8 | 121,557 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2024 | 2,236 | 48,202 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2024 | 2,236 | 6,709 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.82 per share. | 15 Aug 2024 | 1,134 | 47,068 (0%) | 0% | 43.8 | 49,692 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2024 | 793 | 46,368 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2024 | 793 | 2,377 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.82 per share. | 15 Aug 2024 | 402 | 45,966 (0%) | 0% | 43.8 | 17,616 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 71,787 | 71,787 | - | - | Performance Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 71,787 | 71,787 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2024 | 820 | 45,991 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2024 | 820 | 0 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.73 per share. | 23 May 2024 | 416 | 45,575 (0%) | 0% | 51.7 | 21,520 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 21,886 | 43,773 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 21,886 | 54,245 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.37 per share. | 15 May 2024 | 9,074 | 45,171 (0%) | 0% | 47.4 | 429,835 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 2,237 | 8,945 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 2,237 | 33,493 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.37 per share. | 15 May 2024 | 1,134 | 32,359 (0%) | 0% | 47.4 | 53,718 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 15.64 per share. | 15 May 2024 | 978 | 30,866 (0%) | 0% | 15.6 | 15,296 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 792 | 3,170 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 792 | 31,658 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.37 per share. | 15 May 2024 | 402 | 31,256 (0%) | 0% | 47.4 | 19,043 | Common Stock |
| Tandem Diabetes Care Inc | F. Sheridan John | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2024 | 819 | 30,181 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | Sheridan John F. | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2024 | 819 | 820 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | Sheridan John F. | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.34 per share. | 27 Feb 2024 | 293 | 29,888 (0%) | 0% | 27.3 | 8,011 | Common Stock |
| Tandem Diabetes Care Inc | Sheridan F. John | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 2,236 | 11,182 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John Sheridan F. | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 2,236 | 30,279 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | F. Sheridan John | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.29 per share. | 15 Feb 2024 | 917 | 29,362 (0%) | 0% | 24.3 | 22,274 | Common Stock |
| Tandem Diabetes Care Inc | John Sheridan F. | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 793 | 28,368 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | Sheridan F. John | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 793 | 3,962 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | Sheridan F. John | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.29 per share. | 15 Feb 2024 | 325 | 28,043 (0%) | 0% | 24.3 | 7,894 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Aug 2023 | 820 | 25,245 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Aug 2023 | 820 | 2,459 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.06 per share. | 28 Aug 2023 | 284 | 24,961 (0%) | 0% | 27.1 | 7,685 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 2,237 | 15,654 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 2,237 | 25,199 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 792 | 5,547 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 792 | 23,236 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.88 per share. | 15 Aug 2023 | 774 | 24,425 (0%) | 0% | 28.9 | 22,353 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.88 per share. | 15 Aug 2023 | 274 | 22,962 (0%) | 0% | 28.9 | 7,913 | Common Stock |
| Acutus Medical Inc | John F. Sheridan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 19,600 | 19,600 | - | - | FORM 4 | |
| Acutus Medical Inc | John F. Sheridan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 8,400 | 24,347 | - | 0 | FORM 4 | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 65,659 | 65,659 | - | - | RSU 2023 05 25 | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 65,659 | 65,659 | - | - | PSU 2023 05 25 | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2023 | 820 | 3,279 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2023 | 820 | 22,728 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.57 per share. | 25 May 2023 | 284 | 22,444 (0%) | 0% | 26.6 | 7,546 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2023 | 8,945 | 17,891 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2023 | 8,945 | 25,002 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.13 per share. | 15 May 2023 | 3,094 | 21,908 (0%) | 0% | 32.1 | 99,410 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2023 | 793 | 6,339 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2023 | 793 | 16,332 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 27.32 per share. | 15 May 2023 | 560 | 15,539 (0%) | 0% | 27.3 | 15,299 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.13 per share. | 15 May 2023 | 275 | 16,057 (0%) | 0% | 32.1 | 8,836 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 819 | 15,287 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 819 | 4,099 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.87 per share. | 27 Feb 2023 | 308 | 14,979 (0%) | 0% | 35.9 | 11,048 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 792 | 7,132 | - | - | Restricted Stock Unit | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 792 | 14,791 (0%) | 0% | 0 | Common Stock | |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.11 per share. | 15 Feb 2023 | 323 | 14,468 (0%) | 0% | 43.1 | 13,925 | Common Stock |
| Tandem Diabetes Care Inc | John F. Sheridan | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2022 | 820 | 4,918 | - | - | Restricted Stock Unit |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges